Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28342127 | 0.98 | MEN1 (0.62) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL28344661 | 0.87 | VCP (0.52) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL30938002 | 0.83 | ADORA1 (0.61) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL6501260 | 0.83 | MEN1 (0.66) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL29416730 | 0.82 | MEN1 (0.59) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL28815668 | 0.82 | MEN1 (0.59) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL28342149 | 0.81 | ADORA1 (0.47) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL13171353 | 0.79 | MEN1 (1.00) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL6643800 | 0.79 | MEN1 (0.60) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 | |
| SCHEMBL4259978 | 0.78 | CTRC (0.77) | MEN1KMT2AADORA1ADORA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | MEN1 4495/4885KMT2A 1216/4885ADORA1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.